13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer
Standard
13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. / Kluth, Martina; Scherzai, Sekander; Büschek, Franziska; Fraune, Christoph; Möller, Katharina; Höflmayer, Doris; Minner, Sarah; Göbel, Cosima; Möller-Koop, Christina; Hinsch, Andrea; Neubauer, Emily; Tsourlakis, Maria Christina; Sauter, Guido; Heinzer, Hans; Graefen, Markus; Wilczak, Waldemar; Luebke, Andreas M; Burandt, Eike; Steurer, Stefan; Schlomm, Thorsten; Simon, Ronald.
in: GENE CHROMOSOME CANC, Jahrgang 57, Nr. 10, 10.2018, S. 504-512.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - 13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer
AU - Kluth, Martina
AU - Scherzai, Sekander
AU - Büschek, Franziska
AU - Fraune, Christoph
AU - Möller, Katharina
AU - Höflmayer, Doris
AU - Minner, Sarah
AU - Göbel, Cosima
AU - Möller-Koop, Christina
AU - Hinsch, Andrea
AU - Neubauer, Emily
AU - Tsourlakis, Maria Christina
AU - Sauter, Guido
AU - Heinzer, Hans
AU - Graefen, Markus
AU - Wilczak, Waldemar
AU - Luebke, Andreas M
AU - Burandt, Eike
AU - Steurer, Stefan
AU - Schlomm, Thorsten
AU - Simon, Ronald
N1 - © 2018 Wiley Periodicals, Inc.
PY - 2018/10
Y1 - 2018/10
N2 - Deletions of chromosome arm 13q belong to the most frequent molecular alterations in prostate cancer. To better understand the role of 13q deletion in prostate cancer we took advantage of our large prostate cancer tissue microarray comprising more than 12 000 cancer samples with full pathological and clinical follow-up data. Fluorescence in situ hybridization with probes for ENOX1 (13q14.11) and the retinoblastoma gene (RB1, 13q14.2) was employed. A 13q deletion was found in 21% of 7375 analyzable cancers. Deletions were always heterozygous and associated with high Gleason grade (P < .0001), advanced tumor stage (P < .0001), high preoperative prostate-specific antigen (PSA) levels (P = .0125), lymph node metastasis (P = .0377), positive resection margin (P = .0064), and early biochemical recurrence (P < .0001). 13q deletions were marginally more frequent in prostate cancers with negative ERG status (22.9%) than in ERG-positive tumors (18.7%; P < .0001). Loss of 13q predicted patient prognosis independently from established prognostic parameters that are available at the time of biopsy (P = .0004), including preoperative PSA level, clinical tumor stage, and biopsy Gleason grade. In summary, the results of our study identify 13q deletion as a frequent event in prostate cancer, which is linked to an adverse phenotype and poor prognosis in this disease.
AB - Deletions of chromosome arm 13q belong to the most frequent molecular alterations in prostate cancer. To better understand the role of 13q deletion in prostate cancer we took advantage of our large prostate cancer tissue microarray comprising more than 12 000 cancer samples with full pathological and clinical follow-up data. Fluorescence in situ hybridization with probes for ENOX1 (13q14.11) and the retinoblastoma gene (RB1, 13q14.2) was employed. A 13q deletion was found in 21% of 7375 analyzable cancers. Deletions were always heterozygous and associated with high Gleason grade (P < .0001), advanced tumor stage (P < .0001), high preoperative prostate-specific antigen (PSA) levels (P = .0125), lymph node metastasis (P = .0377), positive resection margin (P = .0064), and early biochemical recurrence (P < .0001). 13q deletions were marginally more frequent in prostate cancers with negative ERG status (22.9%) than in ERG-positive tumors (18.7%; P < .0001). Loss of 13q predicted patient prognosis independently from established prognostic parameters that are available at the time of biopsy (P = .0004), including preoperative PSA level, clinical tumor stage, and biopsy Gleason grade. In summary, the results of our study identify 13q deletion as a frequent event in prostate cancer, which is linked to an adverse phenotype and poor prognosis in this disease.
KW - Adult
KW - Aged
KW - Biomarkers, Tumor
KW - Chromosome Deletion
KW - Chromosomes, Human, Pair 13
KW - Gene Deletion
KW - Humans
KW - In Situ Hybridization, Fluorescence
KW - Male
KW - Middle Aged
KW - NADH, NADPH Oxidoreductases
KW - Neoplasm Grading
KW - Neoplasm Recurrence, Local
KW - Prognosis
KW - Prostate-Specific Antigen
KW - Prostatic Neoplasms
KW - Retinoblastoma Protein
KW - Tissue Array Analysis
KW - Journal Article
U2 - 10.1002/gcc.22645
DO - 10.1002/gcc.22645
M3 - SCORING: Journal article
C2 - 29923647
VL - 57
SP - 504
EP - 512
JO - GENE CHROMOSOME CANC
JF - GENE CHROMOSOME CANC
SN - 1045-2257
IS - 10
ER -